Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The gross margin is N/A as of Tuesday, October 6, 2026.
GROSS MARGIN
N/A
Market Cap
$1.41B
Gross Margin
100.00%
TTM Avg
100.00%
3Y Avg
75.15%
5Y Avg
50.10%
Market Cap
$1.42B
Gross Margin
98.97%
TTM Avg
9.74%
3Y Avg
-353.69%
5Y Avg
-246.22%
Market Cap
$1.42B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$1.40B
Gross Margin
14.79%
TTM Avg
13.21%
3Y Avg
12.77%
5Y Avg
12.70%
Market Cap
$1.44B
Gross Margin
83.12%
TTM Avg
85.05%
3Y Avg
87.98%
5Y Avg
90.85%
Market Cap
$1.44B
Gross Margin
17.33%
TTM Avg
13.16%
3Y Avg
12.65%
5Y Avg
13.31%
Market Cap
$1.39B
Gross Margin
-91.00%
TTM Avg
-566.75%
3Y Avg
-1506.60%
5Y Avg
-994.02%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | $1.42B | N/A | N/A | N/A | N/A |
| Taysha Gene Therapies, Inc. (TSHA)vs › | $1.41B | 100.00% | 100.00% | 75.15% | 50.10% |
| AnaptysBio, Inc. (ANAB)vs › | $1.42B | 98.97% | 9.74% | -353.69% | -246.22% |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.42B | 0.00% | 0.00% | 0.00% | 0.00% |
| The Pennant Group, Inc. (PNTG)vs › | $1.40B | 14.79% | 13.21% | 12.77% | 12.70% |
| Ultragenyx Pharmaceutical Inc. (RARE)vs › | $1.44B | 83.12% | 85.05% | 87.98% | 90.85% |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.44B | 17.33% | 13.16% | 12.65% | 13.31% |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.39B | -91.00% | -566.75% | -1506.60% | -994.02% |
| Certara, Inc. (CERT)vs › | $1.45B | 58.33% | 60.70% | 60.53% | 60.29% |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.46B | 0.00% | 50.00% | 25.00% | 25.00% |
Gross Margin
N/A
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
